ReviewMedical oncology (Northwood, London, England)2012
Extraperitoneal response to intraperitoneal immunotherapy with catumaxomab in a patient with cutaneous lymphangiosis carcinomatosa from ovarian cancer: a case report and review of the literature.
Review in Medical oncology (Northwood, London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 13 citations in OpenAlex.
- LncRNA SNHG8 induces ovarian carcinoma cells cellular process and stemness through Wnt/β-catenin pathway.Cancer biomarkers : section A of Disease markers · 2020Article
- Cutaneous Metastases in Ovarian Cancer.Cancers · 2019Review
- Capn4 regulates migration and invasion of ovarian carcinoma cells via targeting osteopontin-mediated PI3K/AKT signaling pathway.Oncology letters · 2019Article
- Article
- Clinical Pharmacology and Translational Aspects of Bispecific Antibodies.Clinical and translational science · 2017Review
- Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report.BMC cancer · 2013Article
- Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer.Targeted oncology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous metastasation is a very rare manifestation of ovarian cancer. We present the case of a 64-year-old woman with recurrent platinum-refractory ovarian cancer and skin metastasis. The patient was treated with intraperitoneal catumaxomab due to massive refractory malignant ascites. Clinical response of the skin metastasis was observed during the intraperitoneal treatment with catumaxomab. Even though response of extraperitoneal tumor sites can be explained with intravascular uptake and a possible vaccination effect, this phenomenon has not been reported up to this point to the best of our knowledge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.